Literature DB >> 19058874

Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.

Jianrong Wang1, Ying Zhao, Mara A Kauss, Samantha Spindel, Huiqin Lian.   

Abstract

1,25-dihydroxyvitamin D3 (vitamin D3) induces differentiation of HL-60 human myeloid leukemia cells; however, the signaling mechanism governing these effects is not fully clear. Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling. Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Pharmacological inhibition of MEK/ERK crippled differentiation in response to vitamin D3. Ectopic overexpression of Akt inhibited MAPK signaling, downregulated cyclin-dependent kinase (CDK) inhibitors p21(Wip1/Cip1) and p27(Kip1) and blunted differentiation in response to vitamin D3 while knockdown of Akt by RNA interference gave reverse effects. Furthermore, knockdown of the CDK inhibitors by siRNA crippled the recruitment of retinoblastoma protein (Rb) from the Raf1-Rb complex and Rb hypophosphorylation, and abolished differentiation in response to vitamin D3. Vitamin D3-induced MAPK signaling mediated upregulation of the CDK inhibitors and Rb, disassociation of Raf1 and Rb, and dephosphorylation of Rb, resulting in Rb binding to transcription factor E2F1 and subsequent differentiation. Finally, knockdown of Rb by siRNA prevented vitamin D3-induced differentiation. Mutating Rb at Ser795 evokes its association with E2F1, indicating the critical role of Rb Ser795 in regulating cell differentiation. Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058874     DOI: 10.1016/j.ejcb.2008.05.003

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  10 in total

1.  Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Authors:  Jessica L Slack; Corey P Causey; Paul R Thompson
Journal:  Cell Mol Life Sci       Date:  2010-08-13       Impact factor: 9.261

Review 2.  Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy.

Authors:  Philip J Hughes; Ewa Marcinkowska; Elzbieta Gocek; George P Studzinski; Geoffrey Brown
Journal:  Leuk Res       Date:  2009-10-06       Impact factor: 3.156

3.  Downregulation of neutral ceramidase by gemcitabine: Implications for cell cycle regulation.

Authors:  Bill X Wu; Youssef H Zeidan; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2009-04-02

Review 4.  Protective cardiovascular and renal actions of vitamin D and estrogen.

Authors:  Pandu R Gangula; Yuan-Lin Dong; Ayman Al-Hendy; Gloria Richard-Davis; Valerie Montgomery-Rice; Georges Haddad; Rihcard Millis; Susanne B Nicholas; Diane Moseberry
Journal:  Front Biosci (Schol Ed)       Date:  2013-01-01

5.  Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling.

Authors:  Jun Du; Chongqi Sun; Zhenzhen Hu; Yu Yang; Yichao Zhu; Datong Zheng; Luo Gu; Xiang Lu
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

6.  MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia.

Authors:  Y-S Zheng; H Zhang; X-J Zhang; D-D Feng; X-Q Luo; C-W Zeng; K-Y Lin; H Zhou; L-H Qu; P Zhang; Y-Q Chen
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

7.  Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.

Authors:  Xiaolan Lian; Yu-Min Lin; Shingo Kozono; Megan K Herbert; Xin Li; Xiaohong Yuan; Jiangrui Guo; Yafei Guo; Min Tang; Jia Lin; Yiping Huang; Bixin Wang; Chenxi Qiu; Cheng-Yu Tsai; Jane Xie; Ziang Jeff Gao; Yong Wu; Hekun Liu; Xiao Zhen Zhou; Kun Ping Lu; Yuanzhong Chen
Journal:  J Hematol Oncol       Date:  2018-05-30       Impact factor: 17.388

8.  Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.

Authors:  Veronica Caraffini; Olivia Geiger; Angelika Rosenberger; Stefan Hatzl; Bianca Perfler; Johannes L Berg; Clarice Lim; Herbert Strobl; Karl Kashofer; Silvia Schauer; Christine Beham-Schmid; Gerald Hoefler; Klaus Geissler; Franz Quehenberger; Walter Kolch; Dimitris Athineos; Karen Blyth; Albert Wölfler; Heinz Sill; Armin Zebisch
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

Review 9.  Role of autophagy in acute myeloid leukemia therapy.

Authors:  Su-Ping Zhang; Yu-Na Niu; Na Yuan; Ai-Hong Zhang; Dan Chao; Qiu-Ping Xu; Li-Jun Wang; Xue-Guang Zhang; Wen-Li Zhao; Yun Zhao; Jian-Rong Wang
Journal:  Chin J Cancer       Date:  2012-08-02

Review 10.  RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis.

Authors:  Armin Zebisch; Veronica Caraffini; Heinz Sill
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.